

# Opportune

Exclusively curated opportunities to re-enter fundamentally strong companies at attractive valuations!

## BUY – Cipla Ltd (CIPLA)

CMP: ₹953 (Upside Potential: 24%) as on 13<sup>th</sup> July 2022

Fair Value (FV): ₹1,180      I      Time Period: 12 months

### Why Invest?

- Fine traction across domestic verticals; there is still scope for improvement.
- Timelines of key US launches gAdvair & gRevlimid in H2FY23 reaffirmed.
- Domestic sales grew 21% yoy in Q4FY22, aided by low base & spurt across core therapies.
- US growth driven by strong traction in respiratory, core formulation business.
- Ex-Covid India growth to be much higher than market in FY23.
- Robust medium-term outlook and attractive valuations.
- Roll-forward to keep FV unchanged at Rs1,180 (22X Mar 24 earnings).

Maintain BUY with FV Rs 1,180

[Read Full Report](#)

This is a synopsis of the Research report issued by Kotak Securities Limited. This is not a comprehensive report and before taking any investment decision we request you to refer the detailed report including disclaimers by clicking here: <https://www.kotaksecurities.com/ksweb/ResearchCall/Fundamental>. Further, the recipient of this material should take their own professional advice before investing.

Disclaimer: <http://bit.ly/2n5AxIE>